دورية أكاديمية
أعرض في EDS

Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.

التفاصيل البيبلوغرافية
العنوان: Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.
المؤلفون: Santry LA; Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada., McAusland TM; Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada., Susta L; Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada., Wood GA; Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada., Major PP; Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada., Petrik JJ; Department of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada., Bridle BW; Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada., Wootton SK; Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
المصدر: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2017 Oct 16; Vol. 9, pp. 181-191. Date of Electronic Publication: 2017 Oct 16 (Print Publication: 2018).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101624857 Publication Model: eCollection Cited Medium: Print ISSN: 2329-0501 (Print) Linking ISSN: 23290501 NLM ISO Abbreviation: Mol Ther Methods Clin Dev Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2017- : Cambridge, MA : Cell Press
Original Publication: New York, NY : Nature Publishing Group, [2014]-
مستخلص: Newcastle disease virus (NDV) is a single-stranded, negative-sense RNA virus in the Paramyxoviridae family. Although primarily an avian pathogen, NDV is a potent oncolytic virus that has been shown to be safe and effective in a variety of preclinical cancer models and human clinical trials. To produce virus for oncolytic trials, NDV is commonly amplified in embryonated chicken eggs and purified from the allantoic fluid. Conventional methods for purifying virus from allantoic fluid often result in relatively low-titer preparations containing high levels of impurities, including immunogenic chicken host cell proteins from allantoic fluid. However, large quantities of virus need to be delivered intravenously to administer oncolytic NDV systemically to mice. This route of administration requires virus preparations that are both highly concentrated (to enable delivery of small volumes) and highly pure (to limit toxic effects from contaminants). Given the accumulation of promising preclinical and clinical data demonstrating the efficacy of NDV as an oncolytic agent, strategies for increasing the titer and purity of NDV preparations are sorely needed to allow for effective intravenous administration in mice. Here, we describe an optimized protocol for the rescue, production, and purification of high-titer in vivo -grade NDV for preclinical studies in mouse models.
References: J Vis Exp. 2013 Oct 11;(80):null. (PMID: 24145366)
Mol Ther. 2008 Nov;16(11):1883-90. (PMID: 18714310)
Nat Rev Drug Discov. 2015 Sep;14(9):642-62. (PMID: 26323545)
Sci Transl Med. 2014 Mar 5;6(226):226ra32. (PMID: 24598590)
Mol Ther. 2009 Apr;17(4):697-706. (PMID: 19209145)
Virology. 1995 Jun 20;210(1):202-5. (PMID: 7793072)
Methods Mol Biol. 2017;1602:141-158. (PMID: 28508219)
Biotechnol Adv. 2011 Nov-Dec;29(6):869-78. (PMID: 21784144)
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93. (PMID: 17535926)
Mol Ther Methods Clin Dev. 2016 Apr 06;3:16018. (PMID: 27088104)
Cancer Res. 2007 Sep 1;67(17):8285-92. (PMID: 17804743)
Gene Ther. 1998 Feb;5(2):181-8. (PMID: 9578837)
Curr Cancer Drug Targets. 2007 Mar;7(2):157-67. (PMID: 17346107)
Nat Commun. 2017 Feb 13;8:14340. (PMID: 28194010)
J Virol. 2011 Jun;85(12):6015-23. (PMID: 21471241)
J Virol. 2016 May 12;90(11):5343-52. (PMID: 27009956)
J Virol. 2001 Dec;75(23):11868-73. (PMID: 11689668)
Gene Ther. 2009 Jun;16(6):796-804. (PMID: 19242529)
J Clin Oncol. 2002 May 1;20(9):2251-66. (PMID: 11980996)
World J Virol. 2016 May 12;5(2):85-6. (PMID: 27175354)
Curr Protoc Microbiol. 2006 Jun;Chapter 15:Unit 15F.2. (PMID: 18770579)
Cancer Immunol Immunother. 2005 Jun;54(6):587-98. (PMID: 15838708)
Clin Cancer Res. 2006 Apr 15;12(8):2555-62. (PMID: 16638865)
J Virol. 2008 Nov;82(21):10556-66. (PMID: 18753210)
Biomedicines. 2016 Jul 20;4(3):. (PMID: 28536382)
Int J Cancer. 2006 Jul 15;119(2):328-38. (PMID: 16470838)
J Mol Med (Berl). 2010 Jun;88(6):589-96. (PMID: 20393691)
J Biomed Biotechnol. 2010;2010:586363. (PMID: 20625497)
Gene Ther. 1999 Jan;6(1):63-73. (PMID: 10341877)
Clin Cancer Res. 2007 Feb 1;13(3):977-85. (PMID: 17289893)
Cancer. 1965 Jul;18:863-8. (PMID: 14308233)
Curr Opin Mol Ther. 2003 Dec;5(6):618-24. (PMID: 14755888)
J Virol. 2007 Nov;81(21):11560-8. (PMID: 17715243)
فهرسة مساهمة: Keywords: Newcastle disease virus; allantoic fluid; intravenous; oncolytic virus; preclinical grade; tangential flow filtration
تواريخ الأحداث: Date Created: 20180321 Latest Revision: 20201001
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5854916
DOI: 10.1016/j.omtm.2017.10.004
PMID: 29556508
قاعدة البيانات: MEDLINE
الوصف
تدمد:2329-0501
DOI:10.1016/j.omtm.2017.10.004